Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Dimensional Fund Advisors Ltd. : Form 8.3 - DCC Energy PLC - Ordinary Shares
-
ADIGHERIN SRL Reports Nearly Double the Net Profit in 2025 as Toro Nero Plans European Expansion
-
Transaction in Own Shares
-
TRUNNANO Launches Upgraded Nano-Modified Lithium-Based Concrete Curing Agent to Revolutionize Floor Hardening and Sealing
-
Result of the auction of 2.00 per cent DGB 2028 and 2.25 per cent DGB 2035
-
PrimeXBT Launches AI-Assisted Trading with MCP Integration, Connecting ChatGPT and Claude to Trading Accounts
-
Notice to Annual General Meeting of SkiStar AB
-
Friendly Technologies Announces Service Orchestration Capabilities to Help Providers Grow Revenue Beyond Broadband
-
Form 8.5 (EPT/RI) - Pharos Energy Plc
-
Form 8.5 (EPT/RI) - Kore Potash Plc
-
fomo Reports Approximately 3.2 Million Users as It Builds a Broader Social Finance Platform
-
Festi hf.: Results of share buyback by way of a reverse tender offer
-
Final amounts of mortgage covered bonds series 10F and 10G to be put on auction
-
VEON’s Banglalink Launches Mukto Pay, Expanding Digital Financial Services in Bangladesh
-
VEON’s Banglalink Launches Mukto Pay, Expanding Digital Financial Services in Bangladesh
-
FHS Living Reveals First Speakers for Paris Edition as Hotelisation Reshapes Europe's Real Estate Sector
-
JLT Mobile Computers Nomination Committee 2027
-
“Building Armenia’s Next Phase of Growth”: the first FT Live forum in Armenia, in partnership with Wilco Wealth Management
-
Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 03 11 2026] - (CGWL)
-
Notification of share transactions by Lumen Investments S.à r.l
-
CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
-
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026
-
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026
-
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
-
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
-
NBPE - Holding(s) in Company
-
PRE ANNOUNCEMENT OF CERTIFICATE AUCTION TENDER
-
UCLOUDLINK GROUP INC. to Report Third Quarter 2026 Financial Results on November 11, 2026
-
Danske Bank A/S, transactions by persons discharging managerial responsibilities
-
Nokia Global Network Traffic Report forecasts AI will drive nearly half of global traffic in 2035
-
CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF GBP 750,000,000 Senior Non-Preferred Callable Fixed Rate Resettable Notes issued on November 29, 2022 (ISIN: FR001400E920)*
-
London Parade Set to Roll-in 2027
-
MathCo Appoints Vijay Raj as Member of MathCo Advisory Board
-
Sampo plc cancels repurchased shares
-
Wolters Kluwer 2026 Nine-Month Trading Update
-
NBPE Announces Transaction in Own Shares
-
Transaction in Own Shares
-
GEVORKYAN Successfully Refinances EUR 30 Million in Bonds. Investor Demand Exceeded the Issue Size.
-
Novo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million
-
Pandora delivers 6% organic growth in Q3 - Guidance narrowed towards upper end
-
Sampo Group’s results for January–September 2026
-
Q1-Q3 Interim Report 2026 - Nykredit Realkredit Group
-
Trading update for 1 January – 30 September 2026
-
STMicroelectronics reveals advanced microcontrollers for real-time power control in AI datacenters and robotics
-
STM32 Summit 2026: STMicroelectronics announces its unified MCU platform, addressing technology convergence across industrial, automotive and physical AI applications
-
Start of Day Message
-
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
-
SIKA DRIVES GROWTH IN TUNNELING AND MINING THROUGH INDUSTRYOS PARTNERSHIP
-
dsm-firmenich reports Q3 2026 trading update
-
Vopak reports strong YTD performance, raises FY 2026 outlook
